drugset
drugset / Trial / NCT04532281

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

NCT04532281 ↗

Phase 0 Recruiting 120 enrolled Zhejiang University Yake Biotechnology Ltd. · collab
NaSingle-groupOpen-labelTreatment

Summary

A Study of Murine CD19 CAR-T Cells Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies.

Timeline

Start
2020-11-01
Primary completion
2023-11-01
Completion
2026-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Murine CD19 CAR-T cells Cell therapy — Intravenous

Indications

acute lymphoblastic leukemia